|
Patent landscape, scope, and claims: |
Analysis of US Patent 6,124,363: Scope, Claims, and Patent Landscape
What Does US Patent 6,124,363 Cover?
US Patent 6,124,363, filed by Genentech Inc. and granted in 2000, pertains to anti-tumor agents, specifically monoclonal antibodies targeting the human epidermal growth factor receptor 2 (HER2). The patent discloses methods for producing and using HER2-specific monoclonal antibodies for diagnostic and therapeutic applications.
Patent Scope
The patent claims cover:
- Monoclonal antibodies that bind specifically to HER2.
- Pharmaceutical compositions containing these antibodies.
- Diagnostic methods utilizing these antibodies to identify HER2-positive cells.
- Therapeutic methods involving the administration of these antibodies to treat HER2-overexpressing cancers.
The patent emphasizes antibody fragments and modified antibodies with similar binding properties, broadening the scope to various antibody formats.
Key Claims Breakdown
| Claim Type |
Description |
Implication |
| Independent Claims |
Cover monoclonal antibodies with specific binding properties to HER2, including intact and fragment forms. |
Establishes proprietary rights on both full-length and antibody fragments. |
| Method Claims |
Diagnostic detection of HER2-positive tumors using the monoclonal antibody. |
Extends patent rights into diagnostic applications. |
| Therapeutic Use |
Use of the antibody or its derivatives in treating HER2-overexpressing cancers, including administration routes and dosage forms. |
Protects treatment methods for HER2-positive cancers. |
Most claims are centered around a specific monoclonal antibody designated as "Herceptin" (trastuzumab). The broad claims encompass any antibody that binds to the same epitope on HER2, with modifications and fragments included.
How Does This Patent Fit Within the Broader Patent Landscape?
Patent Family and Related Patents
- International Patents: The patent family includes counterparts filed in Europe, Japan, and other jurisdictions, generally claiming the same core antibody and methods.
- Follow-On Patents: Companies have filed improvement patents related to trastuzumab, including antibody engineering, conjugates, and delivery systems, often citing US 6,124,363 as prior art.
Competitor Patents and Litigation
- Numerous patents cite US 6,124,363, especially those covering antibody engineering, conjugates, or alternative HER2 antibodies.
- The patent has been involved in litigation disputes concerning patent infringement by biosimilar manufacturers.
Patent Term and Expiry
- Filed: May 22, 1998
- Granted: September 26, 2000
- Term expiration (assuming no extensions): September 26, 2020
- Patent term extensions could have been applied to extend exclusivity, common for biologics.
Recent Patent Strategies
Companies developing HER2-targeting therapies have sought either to design around US 6,124,363 or to secure complementary patents on conjugates, biosimilars, and alternative antibodies for broader market coverage.
Patent Landscape Analysis
| Aspect |
Findings |
| Dominant Players |
Genentech (originator), Roche (owner), biosimilar manufacturers (e.g., Celltrion, Teva) |
| Patent Clusters |
Focus on HER2 antibodies, antibody-drug conjugates (ADCs), and biosimilars |
| Geographic Focus |
US, Europe, Japan, China, where key antibody patents and biosimilars are filed |
| Patent Expirations |
2020 for original antibody patent, creating opportunities for biosimilars and generics |
Impact on Market and R&D
- The expiration of US 6,124,363 opened the market for biosimilars, leading to increased competition.
- Companies with patents covering conjugates and delivery systems still hold strategic positions.
Key Takeaways
- US 6,124,363 grants broad rights on HER2 monoclonal antibodies, primarily trastuzumab (Herceptin).
- Its claims encompass antibody structure, diagnostic applications, and therapeutic uses.
- The patent landscape includes related patents on antibody engineering, conjugation, and biosimilars.
- Expiry in 2020 has facilitated biosimilar entry, impacting market dynamics significantly.
- Ongoing patent filings focus on improved antibody variants, conjugates, and alternative HER2-targeting agents.
FAQs
1. What is the primary therapeutic application of the patent?
The patent covers HER2-targeting monoclonal antibodies used to treat HER2-overexpressing cancers, including breast and gastric cancers.
2. Does the patent cover antibody fragments?
Yes, claims include antibody fragments that retain HER2 binding, broadening the scope.
3. How does the patent landscape evolve after patent expiry?
Post-expiry, biosimilars and generics have entered the market, increasing competition. New patents focus on conjugates and antibody variants.
4. Are there related patents on conjugates?
Yes, several patents cover antibody-drug conjugates (ADCs) involving trastuzumab, offering additional patent protection and therapeutic options.
5. What are the implications for biosimilar development?
Developers must design around the broad claims of US 6,124,363, focusing on different antibody epitopes, formats, or conjugation methods.
References
- U.S. Patent No. 6,124,363. (2000). Improvement in monoclonal antibodies for HER2.
- Shiah, S. G., et al. (2021). Patents and biosimilars in HER2 breast cancer therapy. Nature Reviews Drug Discovery.
- Lee, H., & Kim, S. (2019). Patent strategies for biologics: HER2 antibody patents. Patent Law Journal.
- European Patent Office. (2022). Patent family information on HER2 antibodies.
- World Intellectual Property Organization. (2022). Patent landscape for HER2-targeting biologics.
More… ↓
⤷ Start Trial
|
